Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK

Current Medical Research and Opinion

Volumn 22, Issue 9, 2006, Pages 1777-1785

  Guest, Julian F ^a,b   Clegg, John P ^a   Smith, Andrew F ^c,d  

^a CATALYST Health Economics Consultants   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c Alcon Laboratories Ltd UK   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Costs; Cromoglycate; Olopatadine; Seasonal allergic conjunctivitis; UK

Indexed keywords

CROMOGLYCATE DISODIUM; GENERIC DRUG; OLOPATADINE; OPTREX; OTRIVIN ANTISTIN; RAPITIL; XYLOMETAZOLINE;

ADULT; AGED; ARTICLE; CHILD; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG DOSE REGIMEN; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; NATIONAL HEALTH SERVICE; SEASONAL ALLERGIC CONJUNCTIVITIS; UNITED KINGDOM;

ANTI-ASTHMATIC AGENTS; CONJUNCTIVITIS, ALLERGIC; CROMOLYN SODIUM; DECISION SUPPORT TECHNIQUES; DIBENZOXEPINS; DRUG COSTS; DRUGS, GENERIC; GREAT BRITAIN; HUMANS; SEASONS;

EID: 33749023346     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115739     Document Type: Article

References (19)

1. Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987;21:1-20
2. Abelson MB, George MA, Garofalo C. Differential diagnosis of ocular allergic disorders. Ann Allergy 1993;70:95-109
3. Allansmith MR, Ross RN. Ocular allergy. Clin Allergy 1998;18:1-13
4. University of Michigan Kellogg Eye Centre 2005. Available online at http://www.kellogg.umich.edu/
5. Leonardi A. Pathophysiology of allergic conjunctivitis. Acta Ophthalmol Scand 1999;228(Suppl):21-3
6. Owen CG, Shah A, Henshaw K, et al. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract 2004;54:451-6
7. Anderson DF. Management of seasonal allergic conjunctivitis (SAC): current therapeutic strategies. Clin Exp Allergy 2001;31:823-6
8. The Eye Centre 2005. Available online at http://www. theeyecenter.com
9. Lafuma A, Smith AF. Cost-effectiveness of olopatadine in seasonal allergic conjunctivitis treatment. Expert Rev Pharmacoeconomics Outcomes Res 2002;2:549-54
10. Katelaris CH, Ciprandi G, Missotten L, et al. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002;24:1561-75
11. Lafuma A, Fagnani F, Nuijten M, Berdeaux G. Costs and consequences of olopatadine 0.1% versus cromolyn sodium 2% in the treatment of seasonal allergic conjunctivitis. Value in Health 2001a;4:514
12. SMC 2006. Scottish Medicines Consortium. Summary of advice on olopatadine eye drops (Opatanol), for use within NHS Scotland. Available on-line at http://www.scottishmedicines. org.uk/press/detail.asp?id=836
13. IMS 2005, London
14. Netten A, Curtis L. Unit costs of health and social care 2004. University of Kent, Canterbury: Personal Social Services Research Unit; 2004
15. NHS Executive Reference Costs 2004. Leeds: Department of Health; 2005
16. BNF (British National Formulary). London: BMA and Royal Pharmaceutical Society of Great Britain; 2005
17. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders Co.; 1980. pp. 228-65
18. Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004;11:17-33
19. Lafuma A, Fagnani F, Nuijten M, Berdeaux G. Costs and consequences of olopatadine 0.1% versus levocabastine 0.05% in the treatment of seasonal allergic conjunctivitis. Value in Health 2001;4:513